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Cytomegalovirus immune evasion by perturbation of
endosomal trafficking
Pero Lucˇin, Hana Mahmutefendic´, Gordana Blagojevic´ Zagorac and Maja Ilic´ Tomasˇ
Cytomegaloviruses (CMVs), members of the herpesvirus family, have evolved a variety of mechanisms to evade the
immune response to survive in infected hosts and to establish latent infection. They effectively hide infected cells from
the effectormechanisms of adaptive immunity by eliminating cellular proteins (major histocompatibility Class I andClass
II molecules) from the cell surface that display viral antigens to CD8 and CD4 T lymphocytes. CMVs also successfully
escape recognition and elimination of infected cells by natural killer (NK) cells, effector cells of innate immunity, either
by mimicking NK cell inhibitory ligands or by downregulating NK cell-activating ligands. To accomplish these
immunoevasion functions, CMVs encode several proteins that function in the biosynthetic pathway by inhibiting the
assembly and trafficking of cellular proteins that participate in immune recognition and thereby, block their appearance
at the cell surface. However, elimination of these proteins from the cell surface can also be achieved by perturbation of
their endosomal route and subsequent relocation from the cell surface into intracellular compartments. Namely, the
physiological route of every cellular protein, including immune recognition molecules, is characterized by specific
features that determine its residence time at the cell surface. In this review, we summarize the current understanding of
endocytic trafficking of immune recognition molecules and perturbations of the endosomal system during infection with
CMVs and other members of the herpesvirus family that contribute to their immune evasion mechanisms.
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INTRODUCTION
To evade host immune surveillance, herpesviruses have
evolved a variety of mechanisms that provide them with the
capability of lifelong survival in infected hosts in the form of
latent infection with the ability to reactivate when the immune
surveillance is compromised.1 These mechanisms are based on
the synthesis of viral gene products that specifically interrupt
the expression, either the synthesis or intracellular processing,
of various effector molecules of the innate and adaptive
immune response.2 A majority of these gene products target
either cellular machineries that present viral antigens to major
effector cells with specific immunity (CD8 T cells, CD4 T cells
and natural killer (NK) T cells)2 ormolecules that contribute to
immune recognition by major effector cells that contribute to
innate immunity (NK cells).3
Cytomegaloviruses (CMVs), members of the herpesvirus
family, encode a relatively large number of gene products that
interfere with primary effector mechanisms. They disrupt the
presentation of antigen to CD8 and CD4 T lymphocytes and
attack ligands that activate NK cells.4 To achieve this goal, they
specifically target immune recognition molecules at the earliest
stages of assembly and intracellular trafficking in the biosyn-
thetic pathway.2,5 However, interference with later stages of
their intracellular life is poorly understood, although it is well
known that CMVs perturb many cellular processes, especially
the vesicular system. Every cellular protein that resides in the
membranous system of the cell has specific features that deter-
mine its intracellular localization and lifetime. Thus, perturba-
tion of the endosomal route of cellular proteins, including
molecules that participate in immune recognition, may result
in distinct cellular routing.
In this review, we will focus on CMV remodeling of the
endosomal system and the consequent perturbation of endo-
cytic trafficking of major immune recognition molecules,
which can contribute to immune evasion mechanisms. First,
we will provide a brief overview of our current understanding
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of the physiology of endocytic trafficking, then we will describe
known CMV effects on endocytic routes of immune recog-
nition molecules and finally, we will give a brief overview of
the mechanisms used by other herpesviruses.
THE ENDOCYTIC PATHWAY
Despite intensive research in the last two decades, the endoso-
mal system and endocytic routes remain poorly understood. In
fact, as increasing data are obtained for that complex pathway,
the number of unresolved issues has also risen. The size and
dynamics of the endocytic pathway differ significantly in vari-
ous cell lines due to an extremely high degree of plasticity.
Figure 1 shows a schematic of the endosomal system and endo-
somal routes relevant to the discussion of immune evasion by
endosomal perturbation.
Internalization and internalization rate
Internalization represents the loss of cell surface molecules as a
net result of the combined effects of endocytosis (entrance of
molecules from the cell surface into the cell interior) and recyc-
ling (return of endocytosedmolecules back to the cell surface).6
Thus, the extent and rate of internalization is determined based
on both the rates of endocytosis and recycling. The endocytic
activity of the plasma membrane is extremely high. The equi-
valent of the cell surface is internalized one to five times per
hour,7 which indicates that endocytic and recycling activity are
highly dynamic and well coordinated. Therefore, if a mem-
brane protein has a constitutively higher endocytic rate than
the recycling rate, more protein will accumulate in the intra-
cellular pool. A decrease in the recycling rate (i.e., by remodel-
ing of the endocytic route during viral infection) will result in a
relocation of plasma membrane protein to the intracellular site
where the trafficking rate is the slowest.
Endocytic pathways and endocytic rates
As mentioned previously, endocytosis can be described as a
movement of membranes from the cell surface into an internal
compartment by the formation of various types of endocytic
invaginations and endocytic carriers. The endocytic rate is not
uniform for the entire plasma membrane and depends on the
membrane composition and molecular machinery used to
form the endocytic invaginations and endocytic carriers. The
most frequently discussed endocytic pathways involve clathrin-
dependent endocytosis, clathrin-independent endocytosis,
macropinocytosis and endocytosis through deep tubular inva-
ginations (Figure 1).
A significant fraction of the plasma membrane concentrates
membrane proteins that contain specific cytoplasmic motifs
(clathrin-dependent endocytic motifs such as the tyrosine-based
motif, the di-leucine-based motif, NPXY and mono/multi-
ubiquitinylation). These motifs are recognized by adaptor pro-
teins (AP-2), leading to rapid endocytosis by the mobilization of
complex machinery containing clathrin to form clathrin-coated
endocytic carriers.8 At every moment, 1%–2% of the plasma
membrane contains clathrin-coated pits, and approximately
50% of the plasma membrane is internalized each hour through
this endocytic route.7 This pathway is used to endocytose many
proteins and receptors (i.e., transferrin receptor (TfR), epi-
dermal growth factor receptor (EGFR)).
Membrane proteins that do not have clathrin-dependent
endocytic motifs are captured into clathrin-independent endo-
cytic invaginations and carriers that are constitutively formed at
the plasmamembrane. A portion of these carriers are associated
with engagement of the protein caveolin (caveolae-dependent
endocytosis). Another portion is associated with the activity of
the small GTPase Arf6 (known as the Arf6-associated pathway),
whereas some carriers are formed by tubular invaginations that
do not associate with Arf6, but require the activity of the small
GTPase cdc42, Arf1 and the actin cytoskeleton, known as
the cdc42-dependent pathway or GEEC (glycosylphosphatidyl
anchored proteins enriched endosomal compartments) path-
way.9–14 Additionally, the plasma membrane contains poorly
characterized deep tubular invaginations15 that ensure the
endocytic uptake and cycling of many membrane proteins.16
With increasing data on clathrin-independent endocytosis, it
is becoming apparent that there are multiple and overlapping
routes for constitutive membrane uptake, and thus, the clas-
sification of clathrin-independent endocytic routes is constantly
changing. Membrane deformations and the development of
endocytic invaginations depend on the lipid composition of
the involved membrane region, engagement of effector mole-












Figure 1 Schematic illustration of the endosomal system and endocytic
pathways. Endocytic carriers and endosomal compartments are loca-
lized in cellular areas that are organized by the actin cytoskeletal net-
work (light blue area) andmicrotubular network (darker blue). The dark
blue area represents the nucleus. Basic types of endosomal invagina-
tions indicate routes of endosomal uptake: DTI, deep tubular invagina-
tions; CDE, clathrin-dependent endocytosis; CIE, clathrin-independent
endocytosis; MP, macropinocytosis. Yellow compartments present
various stages of endosomal maturation: EE, early endosomes; EE/SE,
early/sorting endosomes; JRC, juxtanuclear recycling compartment;
MVB, multivesicular bodies; LE, late endosomes; LY, lysosomes.
Endosomal recycling routes are labeled in red: rrp, rapid recycling
pathway; frp, fast recycling pathway; srp, slow recycling pathway; lerp,
late endosomal recycling pathway.
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membrane proteins are organized in different types of micro-
domains (sphingomyelin organized microdomains,17 tetraspa-
nin-rich microdomains18) and nanoclusters of various sizes and
composition.19 The composition of membrane microdomains
determines the mode of membrane deformation and develop-
ment of endocytic invaginations, including the engagement of
various components of the endocytic machinery that are avail-
able in the cytosol. Large lipid-organized areas of the membrane
(lipid rafts) will certainly require a distinct machinery for
deformation, budding and scission compared with lipid-disor-
dered areas. Therefore, several different endocytic rate constants
of constitutive endocytic uptake can be expected based on the
heterogeneity of the membrane composition.
In addition to endocytic uptake by clathrin-dependent and
clathrin-independent mechanisms, a significant portion of the
plasma membrane is also internalized by macropinocytosis
(Figure 1),membrane ruffles that are formed at particular types
of membrane subdomains.20 These ruffles also mediate uptake
of extracellular fluid and cargo molecules in the fluid (i.e.,
dextran and albumin).
Taken together, it is clear that the overall endocytic rate is a
composite of several endocytic activities that occur simulta-
neously at the plasma membrane: the rate of clathrin-dependent
endocytic uptake, rates of constitutive membrane uptake via
clathrin-independent endocytic carriers and deep tubular inva-
ginations, and the rate of macropinocytic uptake.
Early endosomal route
After endocytic uptake, clathrin-coated endocytic carriers are
rapidly uncoated and fuse together. Their phospholipid com-
position changes (i.e., acquire phosphatidylinositol 3-phos-
phate) and they bind the small GTPase Rab5 and early
endosomal antigen 1 (EEA1), are tethered to microtubules
and become classical early endosomes (Figure 1).21 The same
events also characterize the route of clathrin-independent
endocytic vesicles. However, it seems that the latter undergo
several pre-early endosomal maturation events, including
the formation of recycling carriers.9–13 These actin network-
associated events are poorly characterized and represent an
area of intensive research. After maturation to the point of
acquisition of EEA1, non-clathrin-derived endocytic carriers
fuse with classical early endosomes and mix cargo molecules
with those being shuttled through the clathrin-dependent
route.9–13,21,22 Early endosomes attached to microtubules tra-
vel towards the cell center while accepting new cargo vesicles
and releasing tubular extensions.22 By enlargement, classical
early endosomes mix cargo materials and form several mem-
brane domains of maturation.
Along the entire early endocytic route, endosomal mem-
branes form recycling endosomal domains that tubulate and
generate recycling endocytic carriers (Figure 1).23 The recycling
of membranes starts early after endocytic uptake, just before
the stage of classical early endosomes. This poorly character-
ized pathway of recycling, known as rapid recycling,24 occurs in
the cortical area and requires the actin cytoskeleton.16 Upon
fusion into classical early endosomes that travel towards the cell
center, early endosomal membranes continuously generate
recycling domains that return cargo (i.e., TfR and EGFR) back
to the cell surface. This route, known as the fast recycling route,
returns both clathrin-dependent and clathrin-independent
cargo molecules, although it appears that at least some cla-
thrin-independent cargo molecules (i.e., major histocompat-
ibility (MHC) I proteins) are recycled via tubular endosomes
that are distinct from classical TfR-loaded recycling car-
riers.25,26 Finally, early endosomes that reach the cell center
segregate a substantial fraction of the membrane cargo into
endolysosomal domains that mature into late endosomes;21
the rest is constitutively transported into enlarged tubular
endosomes that concentrate around the cell center, known as
the juxtanuclear recycling compartment (JRC).21,22 The JRC
cargo molecules are slowly recycled back to the plasma mem-
brane (slow recycling pathway, Figure 1).
Recycling from the early endosomal system occurs continu-
ously at a rate that counteracts the high rate of endocytic
uptake. If an equivalent of the plasma membrane is endocy-
tosed one to five times per hour, the majority of the endocy-
tosed membranes should be returned via recycling at a similar
rate because only,5% of the plasma membrane is newly syn-
thesized each hour.7 Thus, the proper functioning and integrity
of the recycling system is a key regulator of the composition of
membrane organelles and the cellular distribution of mem-
brane proteins.
Late endosomal route
During their movement along microtubules, early endosomes
enlarge by absorbing incoming early endosomal carriers.21,27
Simultaneously to the constant generation of recycling domains,
early endosomes generate an endolysosomal domain that is
characterized by inward budding and the formation of intra-
luminal vesicles (Figure 1). This domain contributes to the
formation of vacuolar early endosomes, often termed sorting
endosomes, which mature into multivesicular bodies (MVBs)
and either exchange cargo with late endosomes or fuse with late
endosomal membranes in a process that remains poorly char-
acterized.21 Late endosomes are considered a highly dynamic
network of vesicular endosomal membranes that mix cargo
molecules and deliver them either to lysosomes for degradation
or to the trans-Golgi network (TGN) for utilization in the secret-
ory pathway.21,28 A fraction of multivesicular endosomes either
develop into specialized lysosome-related organelles29,30 or con-
stitutively reach the cell surface and recycle late endosomal
cargo to the plasmamembrane31 (lerp, late-endosomal recycling
pathway, Figure 1). Intraluminal vesicles are released in the
extracellular milieu as exosomes during the process known as
exocytosis.21,32
Regulation of endosomal dynamics
Endosomal carriers are formed by membrane deformations
caused by changes in the membrane lipid composition (cata-
lyzed by lipid-modifying enzymes) with the assistance of a set of
cytosolic proteins or by motor proteins that attach membranes
to the cytoskeleton.33 In addition to membrane deformations,
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the formation of endosomal compartments requires a series of
fission and fusion events along the endosomal routes in which
membrane and luminal components are exchanged and sorted.
All of these events are initiated by regulatory small GTPases in
the Rab and Arf family, which attach to the membrane and
recruit a series of effector proteins34,35 (Figure 2).
Scission of endocytic carriers from the plasma membrane
and their fusion into/with early endosomes, including pre-
early endosomal events and rapid recycling events, is regulated
by Arf1 and Arf6 GTPases.23,24 The binding of Rab5 to early
endosomes is essential for their maturation, including fusion
and microtubule attachment, whereas the binding of Rab4 and
Rab35 creates recycling domains that enables the production
and release of recycling vesicles and facilitates fast recycling.
The attachment of Rab11 to early endosomes leads to the
formation of tubular extensions that convert early endosomes
into a network of recycling tubules (JRC) and facilitate slow
recycling. The process of slow recycling is complex and involves
the concomitant activation of Rab11, Rab22a and most likely
Arf1 and Arf6 GTPases.25,36 Replacement of Rab5 on early
endosomes with Rab7 generates endolysosomal domains that
bud extensively into the lumen of endosomes to form enlarged
vacuolar and multivesicular endosomes that mature into late
endosomes. The attachment and activation of Rab7b on late
endosomes results in the formation of an endosomal domain
with the capacity to generate endocytic carriers that travel
towards the TGN,37 whereas the attachment of Rab27b and
Rab27a leads to the formation of secretory endolysosomes
and late endosomal recycling and exocytosis.29,31,32 The
remaining late endosomes with attached Rab7 fuse with lyso-
somes and create degradation organelles38 (Figure 2).
The recruitment of regulatory proteins onto endosomal
membranes is determined by the biochemical composition of
the membrane (i.e., lipid composition) and activity of guanine
nucleotide exchange factors and GTPase-activating proteins.
The attachment of activated regulatory proteins is followed by
the replacement and activation of effector proteins that change
the physiological properties of the membrane, including its
capacity for deformation, motility, fusion/fission, internal bud-
ding, tubulation and vacuolization, among others.34,35 Similar
principles operate in the secretory pathway (Figure 2).
Routes of cargo molecule trafficking
Based on the composition of the endosomal system and the
complexity of the regulatory network, it is clear that the traf-
ficking of cargo molecules depends on many steps along the
endocytic pathway. Thus, the routes of cellular proteins are not
uniform and should be explored for every protein molecules.
Several examples of relatively well-characterized routes are out-
lined in Figure 3.
Some cell surface receptors that contain specific motifs in
their cytoplasmic domain that can recruit the AP-2 complex
are constitutively taken up into clathrin-coated endocytic car-
riers that facilitate their rapid endocytic uptake.39 An example





















Figure 2 Regulation of endosomal trafficking.Major regulatory proteins
that shape endosomal and secretory pathway membranes and deter-
mine dynamics the extent of membrane flow. Endosomal compart-
ments are indicated in white, and secretory pathway compartments






Figure 3 Endocytic routes of some well characterized cargo proteins.
(a) Tf-TfR, transferrin receptor (TfR) with bound ligand transferrin (Tf),
route of clathrin-dependent cargo molecules that recycle via the fast
and slow early endosomal recycling route; (b) EGF–EGFR, epidermal
growth factor receptor with bound ligand (EGF), route of clathrin-
dependent receptors that follow the late endosomal route when asso-
ciated with ligand (red route) or recycle via early endosomes when
unassociated with ligand; (c) LDL–LDLR, low-density lipoprotein recep-
tor with bound ligand (LDL), route of receptor molecules that traffic into
late endosomes when associated with ligand (red route) or rapidly
recycle in the actin-dependent area when dissociated from ligand
(green route); (d) CD63 route, a representative late endosomal resident
protein that cycles between late endosomes and the plasma mem-
brane; (e) GPI (glycosylphosphatidyl inositol)-anchored proteins (GPI-
APs) follow a different route when associated with lipid rafts (rGPI-APs,
red route) than those that reside in a lipid-disordered membrane envir-
onment (nrGPI-APs, green route); (f) the route followed by CD44 is an
example of proteins that rapidly cycle in the cortical area of the cell
(actin-dependent). Orange area, actin-dependent area; blue area,
microtubule-dependent area.
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endosomal and juxtanuclear recycling route (Figure 3a). The
route of some receptors, such EGFR, depends on ligand bind-
ing (Figure 3b). Unoccupied receptors are constitutively inter-
nalized via a clathrin-independent mechanism and mainly
recycled back to the cell surface from early endosomes, the
juxtanuclear recycling compartment or late endosomes40
(Figure 3b, green route). Ligand-associated EGFR is rapidly
endocytosed by clathrin-dependent carriers that fuse with early
endosomes and mature into late endosomes in which EGF/
EGFR are trapped in intraluminal vesicles that are destined
for degradation after fusion with lysosomes40 (Figure 3b, red
route). Lysosomal targeting and degradation of EGF/EGFR is
associated with ubiquitination of the receptor.41
After binding of lipoproteins at the cell surface, the LDL
receptor is rapidly internalized via clathrin-dependent endo-
cytosis, dissociated in pre-early endosomes and recycled back
to the cell surface42 (Figure 3c, green route). Released lipopro-
teins (LDL) continue trafficking in early endosomes towards
late endosomes, which contain the cellular machinery for the
extraction of cholesterol and its routing towards various intra-
cellular destinations43 (Figure 3c, red route).
Late endosomal resident proteins, such as CD63, Lamp1 and
CD83, contain a tyrosine-based lysosomal-targeting motif44
that targets them and is retained in late endosomes
(Figure 3d). Upon fusion of a subset of late endosomes with
the plasma membrane (late endosomal recycling route), the
recycled proteins are rapidly internalized via clathrin-depend-
ent endocytosis into early endosomes and routed toward late
endosomes.30
The trafficking route ofmembrane proteins that are attached
to the plasma membrane by the GPI moiety (GPI-AP) depends
on their localization in the membrane. When they partition
into a lipid-disordered membrane microenvironment, they
are endocytosed by the clathrin-independent pathway into
GEECs, routed into the juxtanuclear recycling compartment
and recycled back to the plasma membrane45 (Figure 3e,
green route). When they partition into a lipid-organized mem-
brane microenvironment (lipid-rafts), they are rerouted from
early endosomes into late endosomes and returned to the
plasma membrane via the late endosomal recycling route46
(Figure 3e, red route).
Some clathrin-independent membrane proteins, such as
CD44, CD98 and CD147 (Figure 3f), are sorted by Hook1
protein and rapidly routed into recycling tubules, avoiding
the classical early and late endosomal routes.16 This process
of continuous recycling results in their prolonged lifetime on
the cell surface.
Endocytic trafficking of antigen-presenting molecules
The trafficking route ofMHCproteins is the best-characterized
route of clathrin-independent cargo molecules. Fully con-
formed MHC I proteins are constitutively endocytosed into
Arf6-associated carriers that fuse with TfR-loaded early endo-
somes.26,47 During trafficking along the early endosomal route,
MHC I proteins are sorted into recycling domains and found
in tubular early endosomes and the juxtanuclear recycling
compartment (Figure 4a). In contrast to TfR, many endocy-
tosed fully conformed MHC I proteins (approximately 40%)
are directed into late endosomes and the degradation
route.48,49 However, endosomal trafficking of MHC I proteins
is more complex because MHC I molecules also can be dis-
played at the cell surface without antigenic peptide (empty
MHC I, open MHC I conformers). In contrast to complete
MHC I, they partition into distinct membrane microenviron-
ments already present in the plasma membrane, endocytose
into distinct endocytic carriers and are excluded from the early
endosomal recycling domains (Figure 4b).48,49 Although the
majority of empty MHC I molecules follow the degradation
route, a portion of them segregate into a specific subset of late
endosomes and undergo recycling via the late endosomal
recycling route (Mahmutefendi_ et al., 2014, unpublished
data).50 Thus, a detailed knowledge of the endocytic routes of
both full and empty MHC I is essential to understand both
antigen presentation mechanisms based on exogenous peptide
loading and virus immune evasion strategies.
MHC IImolecules have two distinct routes. NascentMHC II
molecules associate with the invariant chain (Ii) in the endo-
plasmic reticulum (ER), which inhibits peptide binding. Most,
if not all, Ii–MHC II complexes travel via TGN to the cell
surface and are rapidly endocytosed by clathrin-dependent
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Figure 4 Endosomal routes of antigen-presenting molecules. (a)
Endosomal route of fully conformed peptide-loadedmajor histocompat-
ibility class I (full MHC I) and (b) peptide-empty MHC I molecules
(empty MHC I) that sample peptide antigens in the cytosol and the
endosomal compartments. (c) Nascent MHC II molecules associated
with the invariant chain (Ii–MHC II) are directed into a late endosome-
derived compartment (MIIC) where they sample peptide antigens (red
route). Peptide-loaded MHC II molecules (pMHC II) rapidly recycle
back to the cell surface after clathrin-independent endocytosis (green
route). Endosomal trafficking of CD1amolecules (d) that follow the early
endosomal recycling route as MHC I molecules, CD1b and CD1dmole-
cules (e) are routed into a late endosome-derived antigen-presenting
compartment (MIIC) from which they recycle back to the plasmamem-
brane, and CD1cmolecules (f) are equally distributed into the early and
late endosomal route and recycled to the cell surface.
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lysosome-like antigen-processing compartment (MHC II com-
partment; MIIC) where Ii is degraded and replaced with anti-
genic peptide. Peptide-loaded MHC II molecules (pMHC II)
are then moved to the cell surface to display antigenic peptides
to CD4T lymphocytes (Figure 4c, red route).51 In contrast to Ii–
MHC II, peptide-loaded MHC II that reach the cell surface are
endocytosed by clathrin-independent endocytic carriers,
rapidly internalized into early endosomes and recycled back
to the cell surface (Figure 4c, green route).51 pMHC II intern-
alize and reach a steady state ratio (80% at the surface, 20%
intracellular) within 5 min, which indicates that cells possess
efficient recycling machinery to maintain this distribution.
pMHC II were found in Arf61, Rab351 and EHD11 elongated
tubules emanating from the plasma membrane.51
CD1 molecules, antigen-presenting molecules that are struc-
turally related to MHC I, follow a route similar to MHC I
proteins (Figure 4d–f). CD1a molecules traffic mainly through
early endosomes and are recycled asMHC I proteins (Figure 4d),
whereas CD1c molecules are equally distributed in early and late
endosomes and recycled back to the cell surface also via the late
endosomal recycling route (Figure 4f).52–54 In contrast, CD1d
and CD1b are sorted mainly into late endosomes, into the same
compartment as MHC II molecules (MIIC), and returned to the
cell surface via the late endosomal recycling route (Figure 4e).54
IMMUNE EVASION ACTIVITIES OF CMVS BY
PERTURBATION OF THE ENDOSOMAL SYSTEM
There is increasing evidence that all members of the herpes-
virus family can modulate some or all effector functions of the
adaptive immune response. This modulation is based on the
downregulation of cell surface molecules that participate in
immune recognition, both on target and on effector cells.
Mechanisms that are based on disruption of the cell surface
egress from the secretory pathway of newly synthesized recep-
tors or ligands are well understood, including responsible viral
gene products.55,56 However, little is known aboutmechanisms
that are based on the perturbation of endosomal trafficking of
receptors and ligands that participate in immune recognition.
This lack of information may be explained by a poor under-
standing of basic endosomal trafficking and endosomal pertur-
bations in infected cells. Thus, in the following section, we
provide an overview of current knowledge on the perturbation
of the endosomal system and endosomal trafficking in CMV-
infected cells. Unfortunately, the available data are insufficient
to create an overall map of immune evasion events in the
endosomal system. In general, viruses can downmodulate cell
surface expression by altering the endocytic properties of a
plasma membrane protein or by affecting the endosomal mat-
uration program and thereby disrupting the physiological
route of a given protein.
The host immune response to CMVs involves both innate
and adaptive arms of the immune system. For efficient
development of the adaptive immune response to CMVs, it is
essential to prime CD81 and CD41 T cells.57 Efficient priming
is based on the presentation of viral proteins by MHC I and
MHC II molecules at the cell surface of either infected cells or
antigen-presenting cells, killing the infected cells or initiating a
specific immune response, respectively. Thus, processing of
viral antigens in the MHC I and MHC II presentation pathway
and recognition ofMHCproteins are decisive targets for CMVs
to evade effective clearance from the host.
MHC I molecules sample endogenous viral antigens that
are processed in the cytosol using a sophisticated mechanism
involving proteasomal degradation and peptide loading onto
nascent MHC I proteins.58 Peptide-loadedMHC I proteins are
displayed at the cell surface and monitored by TCR/CD3 com-
plexes on CD81 T lymphocytes. Thus, interference with pep-
tide loading and trafficking of MHC I proteins to the cell
surface is an efficient immune evasion strategy that evolved
in CMVs (Figure 5). Additionally, cell surface MHC I proteins
are constitutively endocytosed into endosomal compartments
and recycled back to the cell surface from various points of the
endosomal system23,49,59 (Figure 4). During endosomal traf-
ficking,MHC I proteins are exposed to the acidified endosomal
environment and mixture of internalized cargo molecules,
including viral peptides,48 which also allows peptide sampling
in the endosomal system and presentation of exogenous anti-
gens (known as cross-presentation).60,61 Therefore, interfer-
ence with the endosomal trafficking of MHC I proteins and
inactivation of the antigen-presenting capacity of the endoso-
mal environment is of particular interest for CMVs (Figure 5).
MHC II molecules are expressed on specialized cells (B lym-
phocytes, dendritic cells, monocytes/macrophages) known as
antigen-presenting cells, which are essential for the develop-
ment of adoptive immune response.62,63 MHC II molecules
sample exogenously derived peptide antigens in a specialized
region of the endosomal system of these cells (MIIC).62,63
Peptide-loaded MHC II proteins are exposed at the cell surface
and constitutively cycle in the endosomal system (Figure 4),
including passage through the acidic gradient of endosomal
compartments and exposure to exogenous peptides obtained
at the cell surface.64 Therefore, forMHC I, remodeling ofMHC
II trafficking in antigen-presenting cells or perturbation of the
antigen-presenting compartment is of particular interest for
CMVs to disrupt the development of the specific immune res-
ponse (Figure 5).
NK cells are critical for defense against CMVs during the
early stages of host infection and prior to the development of
an effective adaptive immune response.3,65 They recognize the
altered cell surface of infected cells and provide protection by
releasing interferon gamma or by direct lysis of infected cells.
Their activity is controlled by a balance of activating (i.e.,
human MICs, ULBPs, RAET1s and murine MULT-1, H60,
RAE-1) and inhibitory (i.e., MHC I) signals that are received
from the cell surface of the infected cell3,4,65,66 (Figure 5). Thus,
modulation of the cell surface expression of activating or inhib-
itory molecules is of particular interest for CMVs to escape
recognition by NK cells.4,65,66 This modulation can be achieved
by reducing their egress to the cell surface from the secretory
pathway or by rerouting their endosomal trafficking and redir-
ecting them from the cell surface into the cell interior (Figure 5).
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Recent studies indicate that NKT cells, a subset of T cells that
co-express T-cell receptors and receptors of NK cells, are
important during the early stages of the immune response to
various pathogens, including herpesviruses.67 NKT cells can be
activated by endogenous and exogenous antigenic lipid and
glycolipid ligands exposed at the cell surface of infected cells
by non-polymorphicMHC I-like proteins from the CD1 family
(Figure 5).68 CD1a samples lipid antigens in the early recycling
endosomes and CD1b samples the late endocytic compart-
ment, whereas Cd1c samples the entire endosomal system in
antigen-presenting cells.52 CD1d samples the endosomal sys-
tem of all cells and thereby is crucial for early surveillance by
NKT cells. Thus, a decrease in the cell surface expression of
CD1 molecules by blocking their synthesis, export to the cell
surface or bymodifying their endosomal trafficking will modu-
late their sampling activity and activation of NKT cells
(Figure 5).
Additionally, for those herpesviruses with tropism to
immune effector cells, it is of interest either to reduce the over-
all expression or to perturb the endosomal trafficking of
immune recognitionmolecules (i.e., TCR/CD3, CD4molecule,
costimulatory molecules, adhesion molecules) and thereby,
reduce their cell surface expression. The spectrum of virus
evasion targets by remodeling of endocytic trafficking is also
confined by the cell tropism.
Murine CMVs (MCMV) remodels endosomal maturation in
the early phase of infection, relocating cell surface MHC I
into an endosomal retention compartment
MCMV encodes several immunoevasion proteins (immunoe-
vasins) that associate with nascent MHC I molecules in the ER
and cooperatively prevent supply to the cell surface of func-
tional MHC I proteins (Figure 5). Protein m152 retains these
proteins in the ER-ERGIC route.69–71 Protein m04 forms com-
plexes withMHC I and escorts it to the cell surface,71,72 whereas
protein m06 redirects it into lysosomes for degradation.71,73
The net result of this cooperative activity is the loss of
MCMV peptide-loaded MHC I proteins from the cell surface
(downregulation of MHC I after prolonged activity of immu-
noevasins) and thus, the prevention of presentation to
CTL.71,74 Experiments with mutant viruses containing a dele-
tion suggest that no other immunoevasins in the MCMV gen-
ome are required for MHC I downregulation.74 However, in
MCMV-infected fibroblasts, almost all of the MHC I proteins
are rapidly cleared from the cell surface at 5–7 h after infec-
tion75 (Figure 6). This loss occurs much earlier than expected
due to the constitutive uptake of cell surface resident MHC I
proteins under inhibited supply conditions by the cooperative
activity of MCMV immunoevasins. Namely, the half-life of cell
surface resident MHC I proteins is longer than 10 h under
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Figure 5 Major effector functions in the immune response to herpesviruses and immunoevasins of cytomegaloviruses that act either in the
secretory or the endosomal pathway. The secretory pathway route is illustrated in orange and the endosomal pathway route in blue. Known
immunoevasins that act in the secretory pathway and the endosomal pathway are listed in the boxes. Not known, indicates that there is evidence for
CMV activity, but the viral gene product is not known. Not determined, indicates that there is no evidence for CMV activity. CMV, cytomegalovirus.
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internalization occurs at a rate of 4%–10% per hour.48,49,76
Thus, in the absence of additional MHC I immunoevasins,
the rapid removal of MHC I from the cell surface in the early
phase of MCMV infection can be explained by perturbation of
the endosomal route.
We have recently shown that MCMV perturbs endosomal
trafficking very early during the infection by acting on distal
parts of the early endosomal route and generating the early
phase retention compartment.75,77 This compartment has the
characteristics of sorting endosomes at the terminal stage of
their maturation. It contains markers of early endosomes
(EEA1 and Rab5) but not markers of late endosomes (i.e.,
LBPA, GM1). It also retains incoming cargo molecules that
travel through both the recycling (i.e., TfR, MHC I) and endo-
lysosomal (EGFR, Lamp1) routes.75 Clathrin-dependent cargo
protein (TfR), which is known to be exhaustively recycled after
endocytosis, is rapidly displaced from the cell surface of
MCMV-infected cells as in uninfected cells (Figure 7a,middle)
and accumulates in the perinuclear area (Figure 7a, right), from
which it cannot leave (Figure 7a, middle) due to recycling
inhibition (Figure 7a, left).75 Clathrin-independent cargo pro-
teins (MHC I) are constitutively internalized in MCMV-
infected fibroblasts at a higher rate than in uninfected cells
(Figure 7b, middle) and accumulate in the perinuclear reten-
tion compartment (Figure 7b, right) together with internalized
TfR.75 Their internalization rate is much higher in MCMV-
infected fibroblasts (Figure 7b, left) due to the decreased recyc-
ling rate,75 suggesting that MCMV infection inhibits recycling
from juxtanuclear endosomes. Furthermore, our recent ana-
lysis of the CD44 route inMCMV-infected cells (Figure 7c, left)
suggests that MCMV infection also perturbs proximal steps in
endosomal recycling. The internalization rate of CD44 also
increases in MCMV-infected cells (Figure 7c, middle), and a
significant fraction of CD44 is displaced in EEA11 perinuclear
endosomes as soon as 4 hrs post-infection (Figure 7c, right).
Thus, it seems that MCMV infection extensively perturbs early
endosomal trafficking during the early phase of infection,
including the formation of recycling endosomal carriers and
maturation of early endosomes into late endosomes, which
results in the development of the perinuclear retention com-
partment. This early endosomal retention is associated with a
reduction of the intracellular content of Rab11 and Rab7,75
small GTPases that are essential for the formation of the recyc-
ling and endolysosomal domains of early endosomes, respect-
ively.34,35 The levels of cell surface proteins, such as MHC I
molecules, depend on the recycling efficiency,48,49 and inhibi-
tion of recycling may result in rapid cell surface loss and
thereby, indirectly enable evasion of immune recognition by
effector T cells.
In addition to MHC I, remodeling of endosomal trafficking
during the early phase of MCMV infection can contribute to
other immunoevasion activities of MCMV, especially the
downmodulation of NKG2D ligands. Three of them (RAE-
1e, MULT-1 and H60) are downregulated from the cell surface
via a mechanism that involves the inhibition of their endoso-
mal recycling.4,78 Thus, additional studies on the endosomal
trafficking routes of other molecules that participate in
immune recognition during MCMV infection are required,
including NKG2D ligands, to better understand the physiology
of MCMV immunoevasion.
Human cytomegalovirus (HCMV) extensively remodels the
endosomal system
Remodeling of the endosomal system in HCMV-infected cells
is associated with the development of the cytoplasmic ‘assem-
bly compartment’.80,81 This compartment is a complex juxta-
nuclear structure that develops by reorganization of cellular
organelles at sites of viral tegument, envelope and nonstruc-
tural protein accumulation to create an environment for the
final tegumentation, envelopment and preparation for shed-
ding of infectious virions.80–86 Recent data indicate that the
assembly complex develops by dramatic rearrangement of the
secretory and endocytic organelles in a way that endosomal
membranes and TGN-derived vesicles are recruited to the cell
center and represent the ‘virus factory’, while the Golgi and
lysosomes are excluded and surround the site of assem-
bly.83,84,87,88 In addition to viral tegument proteins80–83,85,86
and envelope glycoproteins,80–82 this compartment also accu-
mulates TGN markers (i.e., TGN46),80,81,83,84,87 redistributed
early endosomal markers (i.e., EEA1, annexin I),84,87 and cargo
molecules that travel via the early endosomal route (i.e.,M6PR,
HRS)87 and the recycling route (i.e., TfR,).87 It does not contain
lysosomal markers (i.e., Lamp1),87 but contains CD6382,83,87,88
and marker of MVBs, which also suggests the recruitment of
MVB membranes to the site of virion assembly. In cell culture,
the assembly complex develops slowly over 3–4 days of remo-
deling before the first virions are released.81,83,84,86 The remo-
deling is a stepwise recruitment and expansion of existing
vesicular membranes and related regulatory components,
which is associated with the perturbation of trafficking routes,
























Figure 6 Rapid downregulation of cell surface MHC I during the early
phase of infection with MCMV. Cell surface expression of H2-Kd mole-
cules was determined by indirect immunofluorescence and flow cyto-
metry using the monoclonal antibody MA-215 with murine embryonic
fibroblasts at various times after treatment with BFA (10 mg/ml) and
after MCMV infection (infection with w.t. MCMV, multiplicity of infection
of 20). BFA, Brefeldin A; MCMV, murine cytomegalovirus.
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The mechanism(s) of membranous organelle remodeling
remains poorly understood. It involves extensive rearrange-
ments of the cytoskeleton and modulation of the expression
of regulatory and effector proteins that shape the endosomal
and vesicular system. It has been shown at later times postin-
fection thatHCMVupmodulates 81 genes and downmodulates
132 cellular genes that affect functions involved in vesicular
trafficking.89 In response to infection, transcription of the
arf1 and arf6 genes and 13 members of the rab family genes
(rab1a, -1b, -2a, -3a, -6a, -7, -13, -18, -21, -23, -31, -34 and
-40b) is downmodulated; in contrast, seven rab family genes
(ray/rab1C and rab2L, -8, -20, -27a, -32 and -38) were upmo-
dulated.89 Thus, a proper understanding of the biogenesis of
the endosomal system will help reconstruct the events that lead
to remodeling of the endosomal and secretory system during


















































































Figure 7 Endosomal routes of clathrin-dependent and clathrin-independent cargo proteins in MCMV-infected cells during the early phase of
infection. (a) The endosomal route of the TfR in MCMV-infected MEFs at 6 h p.i. (left). The cell surface levels of TfR (middle) were determined by
flow cytometry using the mAb R17 217.1.3 (ATCC TIB-219; anti-rat IgG FITC as secondary antibody) after pulse labeling (60 min at 4 uC) and 0–
60min internalization at 37 uC. Confocal images (right) of the intracellular distribution of internalized TfR after cell surface labeling at 4 uC with the
mAbR17 and0–60min internalization at 37 uC. A short acidwash (pH2.0) was performed to remove un-internalizedmAb–TfR complexes from the
cell surface before staining with anti-rat IgG-AF555. (b) The endosomal route of MHC Imolecules inMCMV-infectedMEFs (left). The internalization
profile of H2-Kdmolecules (middle) in uninfected and6 h-infectedMEFs determined by flow cytometry after labeling at 4 uC (60min) withmAbMA-
21579 and internalization at 37 uC for 0–60 min.48 Anti-mouse IgG-FITC was used as a secondary antibody. Confocal images (right) of the cell
surface and intracellular Kd of uninfected and MCMV-infected MEFs (4, 6 and 8 h p.i.). The cell surface and intracellular Kd were stained in intact
and Triton X-100-permeabilized cells with mAb MA-215 and anti-mouse IgG2a AF555 (red fluorescence). Infection was verified by simultaneous
staining of the MCMV IE1 using mAb CRO-10177 and anti-mouse IgG1 AF488 (green fluorescence). (c) The endosomal route of CD44 protein in
MCMV-infected cells at 6 h p.i. (left). The internalization profile of CD44 (middle) in uninfected and 6-h-infected MEFs determined by flow
cytometry after labeling at 4 uC (60 min) with mAb IM7 and internalization at 37 uC for 0–60 min. Anti-rat IgG-FITC was used as the secondary
antibody. Confocal images of the intracellular distribution of CD44 inMCMV-infected cells at 2 and 4 h p.i. (right). Fixed and permeabilized infected
cells were simultaneously stained with mAb IM7 (CD44) and mAb against EEA1 (Zymed Laboratories, San Francisco, CA, USA) followed by the
secondary reagents anti-rat IgG AF555 (red fluorescence) and anti-chicken Ig AF488 (green fluorescence), respectively. EEA1, early endosomal
antigen 1; IE1, immediate early 1 protein; mAb, monoclonal antibody; MCMV, murine cytomegalovirus; MEF, murine embryonic fibroblast; p.i.,
post-infection; TfR, transferrin receptor.
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infection expands existing compartments or generates a novel
hybrid compartment with both endosomal and TGN prop-
erties. Recent data suggest that HCMV may expand transport
vesicles between endosomes, TGN87 and late endosomal-
derived MVBs.80,83,90 Consistent with these findings, it was
shown in HCMV-infected cells that there a threefold increase
in the expression of Rab27a,91 a small GTPase that regulates
secretion via late endosome-derived lysosomal-related orga-
nelles.29 The association of Rab27a with the assembly complex
suggests that HCMV exploits the machinery of endolysosomal
secretion for its assembly. Upregulation of Rab27a is also assoc-
iated with heterotypic fusion of Rab111 membranes (early
endosomal membranes of the recycling route) with Rab27b1
multivesicular bodies (late endosomal subset that generate
secretory endosomal organelles).29,31,91 The process can be
initiated by viral glycoproteins that recruit endosomal effector
proteins, i.e., HCMV gM forms a dimer with gN and interacts
with the Rab11 effector protein FIP4 (family of interacting
protein 4) to form an intracellular ternary complex in the juxta-
nuclear recycling compartment.92 In addition, it has been
shown recently that HCMV encodes multiple microRNAs
(miRNAs US5-1, US5-2 and UL112-1) to target various com-
ponents that shape the vesicular pathway (i.e., Rab5c, Rab11a
and Cdc42) and thereby, coordinately reorganize secretory
pathway and perhaps endosomal organelles.93
Present data restrict the effect of HCMV on MHC I
expression to the earliest stages of MHC I assembly and
trafficking in the secretory pathway
HCMV encodes multiple genes to evade MHC I antigen pre-
sentation and immune recognition by CD81 cytotoxic T lym-
phocytes (Figure 5). Similarly to MCMV, HCMV infection
eliminates cell surface MHC I expression by preventing the
supply to the cell surface of newly formed peptide-loaded
MHC I proteins by affecting several steps in MHC I biogenesis
and transport (Figure 8). The product of the HCMV US6 gene
attacks the TAP (transporter associated with antigen presenta-
tion) complex and blocks peptide loading onto MHC I mole-
cules in the ER,94 while products of the US3 and US11 genes
dislocate newly synthesized MHC I heavy chains from the ER
into the cytosol for degradation.95,96 MHC I proteins that suc-
cessfully assemble and escape destruction are captured by the
US3 gene product and retained in the ER.97,98 The cooperative
activity of HCMV immunoevasins would result in a gradual
loss of MHC I from the cell surface with kinetics that corre-
spond to their constitutive internalization rate (5%–10% per
hour49). These kinetics occur in cultured fibroblasts in which
HCMV replication is slow.99 Although there is no evidence that
perturbation of the endosomal route contributes to the clear-
ance of MHC I proteins from the cell surface, HCMV appears
to perturb the same endosomal routes of other cellular proteins
as MCMV. Consistent with these findings, recent data indicate
that HCMV inhibits TfR recycling86 and rapidly downregulates
EGFR expression.100
In conclusion, in cells in which the replication cycle of
HCMV is slow, the effect of HCMV immediate early gene
products on MHC I in the secretory pathway is sufficient to
ensure MHC I eradication from the cell surface. However, in
cells with a much faster replication cycle, endosomal remodel-
ing should contribute significantly as an immunoevasion
mechanism. This phenomenon has been shown for murine75
and rat CMV infection,101,102 but should also be considered for
HCMV infection in vivo. The reputation of HCMV as a slowly
replicating virus is based on the development of a cytopathic
effect in cell culture. However, studies in vivo suggest that the
replication of HCMV in vivo is highly dynamic, especially in
immunocompromised patients.103
HCMV inhibits late endosomal recycling and prevents egress
of peptide-loadedMHC II proteins from the peptide-loading
compartment during productive and latent infection
In addition toMHC I trafficking, HCMV has evolved mechan-
ism(s) that alter MHC II expression. These mechanisms are
based on remodeling of their endosomal route and do not
relate to known mechanisms that downregulate MHC I in
the secretory pathway.
HCMV infection reduces cell surface expression of MHC II in
dendritic cells,104,105 monocytes/macrophages106,107 and profes-
sional antigen presenting cells (mature Langerhans cells).108
These cells are major targets for HCMV infection, latency and
reactivation. The mechanism of MHC II cell surface down-regu-
lation was successfully characterized in transfected astrocytoma
cells that constitutively express MHC II.109 In HCMV-infected
astrocytoma cells109 and HCMV-infected mature Langerhans
cells,108 the early stages of endosomal transport (including recyc-
ling), entry into a peptide-loading compartment (MHC II) and
assembly and peptide loading of MHC II are unaltered, but the
latest stages of their transport are blocked. Peptide-loaded MHC
II is retained in the perinuclear area and sequestered in an
enlarged peptide-loading compartment with defective traffick-

















Figure 8 Known sites of herpesvirus activity in the intracellular traffick-
ing of immune recognition molecules. Members of the herpesvirus
family block the exit of newly synthesized immune recognition mole-
cules from the biosynthetic pathway (green), the return of internalized
molecules via early endosomal recycling (orange) and late endosomal
recycling (grey), or the rerouting from the early endosomal recycling
route to the late endosomal route and lysosomal degradation (blue).
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addition to MHC II, HCMV is also sequestered in the same
location as the costimulatory molecules CD80, CD83 and
CD86,108,110–112 suggesting that HCMV attacks the late endoso-
mal recycling route. All of these effects are not induced by the
MHC I immunoevasins that localize in US1–US11 region.109 In
addition to endosomal perturbation, the immunoevasion
potential of HCMV is further extended to cytoskeletal remodel-
ing. In HCMV-infected mature Langerhans cells, the loss of
peptide-loaded MHC II from the cell surface is associated with
the loss of cytoskeletal extensions that provide support for den-
drites of Langerhans cells,108 which reduces their ability to clus-
ter with T cells and decreases their capacity to stimulate T-cell
proliferation.113,114
Immunoevasion by endosomal perturbation is even more
attractive in latently infected cells in which the expression of
HCMV genes is restricted to CMV latency-associated tran-
scripts, which are encoded by the immediate early (ie1/ie2)
region of the viral genome.115 These transcripts are expressed
in natural and experimental latent infection. In experimental
latent infection of granulocyte-macrophage progenitor cells in
culture that do not express productive viral replication gene
products, the cell surface level of MHC II is markedly reduced,
synthesis and processing occur normally, andMHC II proteins
together with HLA-DM are redistributed and retained within
punctate cytoplasmic vesicles.116 This reduction of cell surface
MHC II is independent of all known immunomodulatory
functions (i.e., in the US2–US11 region mutant, MHC II is
downregulated and is not expressed during latent infection).116
Thus, it appears that HCMV also perturbs the endosomal traf-
ficking of MHC II during latent infection. The mechanism of
perturbation is unclear. However, the observation that 50% of
latently infected cells down-regulate MHC II and only 2%-3%
contain of them contain latency associated transcripts suggests
that that down-regulatioion information may be distributed in
cell culture, perhaps by miRNA.
HCMVevadesNK cell-mediated lysis by a variety of different
mechanisms that are not associated with endosomal
perturbation
HCMV has evolved a variety of different mechanisms to evade
NK cell activation66 that are based either on the expression of
molecules that engage inhibitory NK receptors or on the down-
modulation of ligands that engage activating NK receptors
(Figure 5). Surface expression of HLA-E enabled by HCMV
UL40, virus-encodedMHC I homologue UL18, tegument protein
pp65, and glycoprotein UL141 are examples of HCMV-encoded
functions that engage inhibitory receptors.66 HCMV also down-
regulates ligands that activate NKG2D (MICs, ULBPs,
RAET1s),117 either by downregulating their transcription by
virus-encodedmicroRNAs (MICB bymiRUL112)118 or by retain-
ing them in the ER/cis-Golgi (MICB, ULBP1, ULBP2 and ULBP6
by UL16)119 or in the Golgi (MICA and ULBP3 by UL142).120
Given that HCMV-infected cells are extremely resistant to
NK cell lysis, it can be anticipated that the number of HCMV
genes possessing NK cell-activating ligands, including HCMV-
modulated cellular functions, will increase with further
research. For example, two additional HCMV genes, US18
and US20, have been recently identified to promote downregu-
lation NK cell-activating ligands by lysosomal degradation121
(Figure 5). This observation is the only association, to our know-
ledge, of a NK immunosubversive function associated with
endocytic trafficking. A further understanding of a HCMV
immunosubversion mechanism via down-modulation of NK
cell-activating ligands, or at least MICs, will require answering
the question of howHCMVdeals with sequence polymorphisms
of MICs (80 alleles of MICA and 33 alleles of MICB). A mech-
anism based on modulation of the endosomal route has been
proposed recently by Agu¨era-Gonza´lez et al.122 The short-term
residence of MCIB at the cell surface of the HCMV-infected cell
may result in its redistribution into a compartment that shares
features with late endosomes/lysosomes, but is functionally and
morphologically distinct.122 Thus, remodeling of endocytic traf-
ficking in concert with known activities of immunoevasins in
the secretory pathway should be considered.
IMMUNE EVASION POTENTIAL OF ENDOSOMAL
PERTURBATION DURING INFECTION WITH OTHER
HERPESVIRUSES
Other herpesviruses also have evolved a variety of mechanisms
to disrupt the cell surface display of immune recognitionmole-
cules. In addition to early identified effects on their biogenesis,
substantial evidence indicates that herpesviruses also target
endosomal trafficking. The sites of immunoevasion activities
of human herpesviruses are indicated in Figure 8.
Several herpesviruses modulate the earliest steps of MHC I
biogenesis and trafficking in the secretory pathway. Herpes
simplex virus 1 and 2 (HSV-1 and HSV-2), members of the
alpha-herpesvirus subfamily, encode the ICP47 protein that
inhibits peptide loading of MHC I proteins in the ER and
thereby prevent the export of MHC I to the cell surface.123,124
Similar tools also evolved in the Epstein–Barr virus (EBV),
Kaposi’s sarcoma-associated virus and murine herpesvirus
68, which are members of the gamma-herpesvirus subfamily.
These viruses encode proteins (EBNA1 of EBV,125 LANA1 of
KSV126 and ORF73 of murine herpesvirus 68127) that suppress
peptide loading of MHC I and prevent the exit of MHC I
proteins from the ER. Varicella-zoster virus, another member
of the alpha-herpesvirus subfamily, acts a bit later in the secret-
ory route of MHC I. It encodes an Us3 homolog that arrests
MHC I in the cis/medial-Golgi and retains it in the perinuclear
area.128
The next step in MHC I trafficking along the secretory path-
way chosen by herpesviruses is their rerouting in the trans-
Golgi towards rearranged late endosomal compartments. In
addition to murine CMV, human herpesvirus 6 (HHV-6)
and HHV-7, beta-herpesviruses, which are closely related to
CMV that infects CD4 T lymphocytes, encode the U21 gene.
The product of U21 associates with properly folded peptide-
loaded classical and non-classical MHC I proteins in the ER
and reroutes them from theGolgi into the endolysosomal com-
partment, thereby effectively removing them from the cell sur-
face.129–131 The U21 protein also binds to NK cell-activating
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ligands (ULBP1, MICA andMICB ligands for NKG2D),131 but
it does not bind to the NKT ligand CD1d.130 U21-expressing
cells sequester MHC I and ULBP1 in a perinuclear location in
late endosomes and facilitate their rapid degradation.130,131
Unlike MCMV m06, U21 does not have a di-leucine motif to
reroute trafficking towards late endosomes, which suggests that
U21 uses an unidentified cellular protein(s) that contains lyso-
somal targeting information in its cytoplasmic tail and binds to
the luminal domain of MHC I and NKG2D ligands.130
In addition to the rerouting activity of U21 in the Golgi,
HHV-6 and HHV-7 encode protein U24, which functions in
the endosomal route. The activity of U24 does not affectMHC I
trafficking but inhibits constitutive recycling of the T-cell
receptor complex (TCR-CD3) in infected CD4 T lymphocytes
and retains them in Rab41 and Rab51 early endosomes.132
Given that U24 also inhibits the recycling of TfR through the
PPXY motif near the amino terminus; it appears that U24-
mediated downregulation of TCR-CD3 results from a general
block in the recycling route used by TCR-CD3 and TfR, but not
in the recycling route used by MHC I.132
Disruption of endosomal recycling or rerouting in early
endosomes and exclusion from the recycling route is a prefer-
able target not only for beta-herpesviruses but also for other
herpesviruses. Endosomal recycling is a key cellularmechanism
to control the number of molecules at the cell surface. In the
case of antigen-presentingmolecules, recycling is a crucial step,
especially for cross-presentation. Perturbation of the recycling
route of antigen-presenting and immune recognition mole-
cules, either directly or indirectly, is therefore a logical target
for herpesviruses (Figure 8).
Studies of HSV-1-infected antigen-presenting cells have
demonstrated that HSV-1 disrupts the endosomal recycling
machinery, which strongly reduces the cell surface expression
of CD1b and CD1d molecules.133,134 Constitutively interna-
lized CD1d molecules are redirected from the recycling route
and accumulate intracellularly with a late endosome phenotype
where they colocalize with viral proteins.133,134 Thus, although
there is no experimental evidence that the same mechanism
affectsMHC I trafficking inHSV-infected cells, there is a strong
indication that the endosomal route of MHC I is affected in
HSV-1-infected cells. It has been shown that HSV-1 Us3 kinase
activity is required for efficient cell surface downregulation of
MHC I proteins in HSV-1-infected cells.135 Us3 does not phos-
phorylate MHC I and cannot downregulate MHC I expression
when over-expressed alone, which suggests that it downregu-
lates cell surface MHC I indirectly.135
Other members of the alpha-herpesvirus subfamily, equine
herpesviruses (EHV-1 and EHV-4)136,137 and bovine herpesvirus
1,138 rapidly downregulate cell surface MHC I very early in
infection by a mechanism that involves enhanced internaliza-
tion, perhaps disrupting their recycling routes. Downregulation
of cell surface MHC I in EHV-1- and EHV-4-infected cells is
observed as early as four hours postinfection and is associated
with the expression of pUL56, a product of ORF1; however, the
mechanism is poorly characterized.137
The endosomal rerouting of cellular proteins that participate
in immune recognition appears to be a dominant immune
evasion strategy of gamma-herpesviruses. Kaposi’s sarcoma-
associated virus encodes ubiquitin ligases (kK3 and kK5,
known as MIR1 and MIR2, respectively) that interact with
transmembrane domains of cell surface MHC I proteins to
catalyze their polyubiquitination and orchestrate their
rapid removal from the cell surface.139,140 Polyubiquitination
redirects constitutive endocytic uptake of MHC I proteins into
the clathrin-dependent pathway, which accelerates their endo-
cytic uptake,141 and excludes internalized MHC I proteins from
the endosomal recycling routes. In early endosomes, ubiquiti-
nylated MHC I proteins are sorted into endolysosomal
domain, rerouted into late endosomes and from there, via
the late endosomal sorting protein TSG-101, delivered into
the lysosomal compartment for degradation.142 It has been
shown that kK5 has a remarkable ability to target and down-
regulate not only MHC I but also many immunoreceptors,
including ICAM-1,143 CD86,143 CD1d,144 MICA/B,145 AICL,145
PECAM,146 ALCAM147 and IFN receptors,148 and thereby, effec-
tively prevent recognition by cells of the adaptive (MHC I and
CD1d restricted NKT cells) and the innate (NKG2D- and
NKp80-restricted NK cells) immune response. In addition to
polyubiquitin-mediated endosomal rerouting to lysosomal
degradation (i.e., MHC I139 and AICL145), some immunorecep-
tors are downregulated by perturbation of the endosomal sys-
tem. For example, Cd1d144 and NKG2D ligandMICA145 are not
degraded, but redistributed and retained in an enlarged intra-
cellular compartment that lacks clathrin, EEA1, Vps-26, Lamp1
and TGN-46.145
EBV encodes a protein, BILF1, which associates with MHC I
at the cell surface and targets it for lysosomal degradation.149 In
contrast to Kaposi’s sarcoma-associated virus kK5, BILF1 does
not mediate MHC I downregulation by polyubiquitin-
enhanced endocytosis and does not reroute them towards lyso-
somes.150 It seems that BILF1 cooperates with other EBV genes
that generally perturb endosomal routes to reduce cell surface
MHC I.150 This perturbation is associated with dislocation and
intracellular retention of MHC I together with the costimula-
tory molecules CD80 (B7-1), CD83 and CD86 (B7-2) but not
MHC II.151
CONCLUSIONS
Remodeling of the endosomal system is a hallmark of infection
with herpesviruses, especially with CMVs. This remodeling is
evident during the latest stages of CMV infection. In HCMV-
infected cells, at least a part of the remodeling is associated with
the development of the assembly compartment; however, very
little is known about perturbations in earlier stages of infection.
These perturbations might be associated with several import-
ant but still unresolved issues in CMV biology, such as cell
tropism, productive infection and latency. A better under-
standing of the physiology of endosomal organelles and intra-
cellular pathways will facilitate our knowledge of endosomal
remodeling during CMV infection. Thus, it is important to
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determine the physiological route of many intracellular pro-
teins to understand the physiology of the infected cell.
The same principles would apply to cellular proteins that
contribute to immune recognition. The primary target for
CMVs will be modulation of antigen presentation in the endo-
somal system, either by retrieval of MHC I loaded with viral
peptides into endosomal compartments or redirection ofMHC
I trafficking and disruption of endosomal peptide loading.
Thus, it is not surprising that CMVs target endosomal recycling
because this recycling is essential for themaintenance ofMHC I
at the cell surface and for the mechanism of exogenous peptide
loading. Still, the peptide-loading endosomal compartment
has not been discovered, and the physiological role of MHC I
proteins lacking peptide remains unknown. Hopefully, research
on MHC I trafficking and exogenous MHC I peptide loading in
infected cells will provide additional insight into the physiology
of exogenous antigen presentation and immune recognition of
infected cells.
Over the last decade, endocytosis research has revealed
enormous complexity of the endosomal system and its func-
tions. The complex molecular network that shapes the endo-
somal system ensures a high degree of plasticity, which makes
interpretation of endosomal functions enormously complex,
especially considering that many conclusions are based on
long-term remodeling by siRNA, dominant-negative mutants
or over-expression of individual molecular players. Thus, the
physiological hierarchy of the molecular mechanisms has been
difficult to establish. Remodeling by viruses, which is usually a
rather fast process, may help to establish the patterns of
molecular activities that shape physiological pathways in the
endosomal system.
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